Speaking of Supply Chain

The episode covers legitimate strategic concepts - deglobalization, dual sourcing, resilience as design rather than reaction - but relies heavily on rephrasing the same core idea (move from reactive to proactive) across multiple segments. Stefan Gotthardt provides some substantive points (e.g., manufacturers exiting unprofitable markets, pricing pressure preventing redundancy), but these are interspersed with considerable restatement and softer observations that don't materially advance understanding.

“risk has become a permanent design condition”

“a contract manufacturer two days ago, and he said, I am declining supplying generic products, specific generic products to customers in Europe because I cannot make any money out of it”

The core thesis - pharma is overglobalized and must regionalize to build resilience - is sound but not particularly novel in 2024-2025 discourse; similar arguments have circulated post-COVID and post-tariff waves. The framing of resilience as a permanent design condition is slightly fresher, but the episode recycles familiar frameworks (supply chain as strategic lever, outside-in hiring from other industries) without sharp contrarian takes or first-principles decomposition.

“pharmaceutical industry really followed a globalization approach”

“supply chain also should be in the lead of strategy because supply chain understands the connectivity of the whole network”

Stefan Gotthardt appears to be a supply chain practitioner with pharma industry experience and enough standing to moderate panels at European Logi Pharma Conference, suggesting relevant operational exposure. However, the transcript provides no credential detail, company affiliation, or scale of responsibility, making it difficult to assess true seniority or whether he is primarily a consultant/speaker versus someone who has run supply chains at scale.

“Stefan Gotthardt, who moderated a powerful discussion at this year's European Logi Pharma Conference”

“I've done it myself for quite some time”

The episode is thin on named companies, concrete data, and quantified examples. A single anecdote about a contract manufacturer exiting ibuprofen production and a vague mention of a global head of supply chain from automotive are the only specific details. No metrics on cost of dual sourcing, timelines for regionalization, percentage of APIs sourced from Asia, or case studies of companies executing deglobalization are provided.

“a pack of chewing gum that is twice more expensive than than a pack of iBook iboproven tablets”

“I have recently spoken to a global head of supply chain who came from automotive”

Ellen Wood asks reasonable setup questions and demonstrates listening (e.g., following up on tariffs, balancing resilience vs. affordability), but rarely pushes back on claims or demands specificity. The conversation flows smoothly but remains largely affirming rather than interrogative. Wood doesn't challenge Stefan's assertions about deglobalization timelines, the feasibility of dual sourcing under pricing pressure, or ask for concrete examples of companies successfully executing the proposed strategies.

“So during the panel, you emphasize the shift from reacting to anticipating. What does that kind of proactive resilience actually look like in practice?”

“How do the leaders justify investing in that kind of redundancy and flexibility when when the pricing pressures are already so intense”